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Diagnosis
TreatmentMitochondrial disorders are a group of clinically heterogeneous diseases, commonly deﬁned by a lack of
cellular energy due to oxidative phosphorylation (OXPHOS) defects. Since the identiﬁcation of the ﬁrst
human pathological mitochondrial DNA (mtDNA) mutations in 1988, signiﬁcant efforts have been spent in
cataloguing the vast array of causative genetic defects of these disorders. Currently, more than 250
pathogenic mtDNA mutations have been identiﬁed. An ever-increasing number of nuclear DNA mutations
are also being reported as the majority of proteins involved in mitochondrial metabolism and maintenance
are nuclear-encoded. Understanding the phenotypic diversity and elucidating the molecular mechanisms at
the basis of these diseases has however proved challenging. Progress has been hampered by the peculiar
features of mitochondrial genetics, an inability to manipulate the mitochondrial genome, and difﬁculties in
obtaining suitable models of disease. In this review, we will ﬁrst outline the unique features of mitochondrial
genetics before detailing the diseases and their genetic causes, focusing speciﬁcally on primary mtDNA
genetic defects. The functional consequences of mtDNA mutations that have been characterised to date will
also be discussed, along with current and potential future diagnostic and therapeutic advances.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Mitochondria are essential double-membraned subcellular orga-
nelles, present in all nucleated mammalian cells. Their primary
function is to support aerobic respiration and produce, by oxidative
phosphorylation (OXPHOS), the bulk of cellular ATP [1]. The OXPHOS
machinery is made up of over 80 different polypeptides, organised
into ﬁve transmembrane complexes. Electrons, resulting from
oxidation of fat and carbohydrates, are shuttled to oxygen along the
ﬁrst four respiratory chain (RC) complexes (CI–CIV), producing water,
and providing the energy necessary to pump protons across the inner
membrane (IMM) from the matrix to the intermembrane space. The
electrochemical gradient thus created enables the ﬁfth RC complex,
ATP synthase, to phosphorylate ADP forming ATP. In addition to
OXPHOS metabolism, mitochondria control cytosolic calcium concen-
tration [2] and regulate apoptotic cell death [3]. They are the major
source of endogenous reactive oxygen species (ROS) [4] and they host
other important biochemical pathways, including the tricarboxylic
acid (TCA) cycle and parts of the urea cycle [5]. Furthermore, these
organelles are central to iron–sulphur cluster biogenesis, the only
entirely conserved function of eukaryote mitochondria [6].sis; DHU, dihydrouridine; H-
brane; L-strand, light-strand;
ondrial DNA; PD, Parkinson's
, respiratory complex; ROS,
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ll rights reserved.Over the last 20 years, mitochondrial dysfunction has been
increasingly recognised as an important contributor to an array of
neuromuscular and neurodegenerative diseases. Because mitochon-
dria are under the dual genetic control of both the mitochondrial and
nuclear genomes, mutations within either DNA molecule may result
in a RC deﬁciency. For this review, we will focus speciﬁcally on
primary mitochondrial DNA (mtDNA) mutations in relation to human
disease. Reviews on nuclear gene defects in mitochondrial disorders
are available [7–9]. After outlining the peculiarities of mitochondrial
genetics and describing the clinical syndromes caused by mtDNA
mutations, we review the current understanding of the molecular
mechanisms of mitochondrial pathogenesis. Finally, recent advances
in the development of potential therapeutic approaches will also be
discussed.
2. Basic mitochondrial genetics
Mitochondrial genetics differ considerably from Mendelian genet-
ics. Uniparental inheritance, cellular polyploidy and a deviation from
the standard genetic code are just some of the peculiarities of
mitochondrial genetics. These unique features strongly dictate the
functional consequences of pathogenic mtDNA mutations.
2.1. Mitochondrial genome
Considered evolutionary relics of ancient bacterial symbionts,
mitochondria have gradually transferred the vast majority of their
genetic material to the nucleus [10]. All that remains is a compact
(16,569bp), double-stranded (cytosine-rich light (L) and guanine-rich
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was fully elucidated in 1981 [11] and further revised in 1999 [12].
Several hundreds or thousands of copies of the mitochondrial genome
are present in a single cell.When allmtDNAmoleculeswithin a cell are
identical, a situation known as homoplasmy prevails. The presence of
two or more mitochondrial genomes results in heteroplasmy.
Originally believed to be discrete entities with their own individual
‘naked’ and free-ﬂoating genetic identity, mitochondria are now
recognised to be dynamic organelles that continuouslymove, fuse, and
divide [13]. Multiple copies (∼6–10) of mtDNA are organised in stable
protein–DNAmacrocomplexes, termed nucleoids, which are primarily
IMMassociated [14,15] andmay be exchanged betweenmitochondria.
Key proteins involved in mtDNA replication, maintenance, repair, and
recombination, such asmitochondrial single-stranded binding protein
(mt-SSB), mitochondrial polymerase γ (POLG), and mitochondrial
transcription factor A (TFAM), are just some of the major constituent
proteins associated with these structures [15–17].
Strictly inherited through the maternal lineage [18], human
mtDNA contains only 37 genes, which encode 13 polypeptides, all
core subunits of RC complexes I, III, IV, and V, and the RNA necessary
for mtDNA translation, namely 2 rRNAs (12S and 16S) and 22 tRNAs.
Nuclear genes encode the remaining ∼70 OXPHOS components, and
all other proteins required for mitochondrial metabolism and
maintenance, which are imported to mitochondria via specialised
import systems [19]. There are no introns within mtDNA genes andFig. 1. Human mitochondrial genome. Represented is a schematic diagram of the 16.6 kb c
mammalian D-loop and transcription termination regions, shown in linear form. The circle
Human mtDNA encodes the 2 mt-rRNAs (red) RNR1 (12S rRNA) and RNR2 (16S rRNA), 22 m
polypeptides: ND1-ND4 and ND4L, subunits of complex I (green), CYTB, a subunit of comple
subunits of complex V (blue). Major noncoding regions of the genome (grey) include the 1.1
is indicated within the D-loop (OH). H-strand transcription is initiated either from HSP1, gen
the guidance of the transcription termination factor MTERF, or from HSP2, generating polyc
produces polycistronic transcripts for this strand and also generates RNA precursors for H-st
in human, mouse and rat that participate in the formation of RNA primers for replication. Tra
TFAM, together with a single subunit RNA polymerase (POLRMT), which forms a heterodim
other regions of the D-loop; however, only binding to the CSB region is shown.almost no intergenic noncoding nucleotides exist, with the exception
of the 1.1 kb displacement loop (D-loop), which contains transcrip-
tional promoters and at least one of the proposed replication origins
(OH) (Fig. 1).
2.2. MtDNA maintenance: replication, transcription, and translation
It is largely accepted that mtDNA is continuously turned over,
independently of the nuclear genome, and its replication does not
coincide with the cell cycle [20]. Evidence of mtDNA replication in
postmitotic tissues (e.g., brain, skeletal muscle) supports this view
[21]. However, increasing reports on the relationship of mitochondrial
function to the cell cycle [22–24] suggest a connection between
mtDNA replication and the cell cycle may well actually exist.
The exact mechanism of human mtDNA replication is still
uncertain. Two distinct mechanisms have been proposed. In the
traditional strand-asynchronous method, replication initiates at the
heavy strand origin (OH), causing displacement of the L-strand from
the H-strand. The former remains single-stranded whilst replication
of the H-strand proceeds almost two-thirds of the way around the
mitochondrial genome, until exposure of the L-strand origin (OL). L-
strand synthesis can then begin in the opposite direction [25]. A
second more conventional replication method has been suggested in
which coupled leading-lagging strand DNA replication, also initiating
at OH, is coordinated [26,27]. In this model, lagging L-strand synthesisircular, double-stranded human mitochondrial genome with an enhanced view of the
represents the heavy (H) strand of the genome and the inner circle the light (L) strand.
t-tRNAs (black bars), identiﬁed by their single letter abbreviation, and 13 essential RC
x III (purple), COI-COIII, catalytic subunits of complex IV (yellow), and ATP6 and ATP8,
kb D-loop, and the origin of L-strand replication (OL). The origin of H-strand replication
erating a short transcript that terminates at the RNR2/MTTL1 boundary (Term) under
istronic transcripts of the entire H-strand. LSP denotes the L-strand initiation point that
rand replication initiation. Conserved sequence blocks (CSBs I-III) are conserved regions
nscription from all promoters requires the upstream binding of transcriptional activator
eric complex with the transcription factor TFB2M (depicted as TFB). TFAM also binds to
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generation of short Okazaki ribonucleotide fragments, subsequently
converted to DNA [28]. The exact mechanism of mtDNA replication is
still debated. However, it is likely that both models exist and their
occurrence may be cell type-dependent, with the leading-lagging
strand model more prevalent in cells which are in a steady-state and
the strand-displacement mechanism more predominant in cells
requiring rapid mtDNA synthesis (e.g., cells recovering from mito-
chondrial depletion) [26,27,29].
MtDNA replication is accomplished by nuclear-encoded factors.
Core components of the mitochondrial replisome include POLG,
consisting of a catalytic subunit with 5′–3′ exonuclease activity
(PolgA) and a processivity subunit (PolgB), Twinkle, with 5′–3′ DNA
helicase activity, and mt-SSB [30].
Mitochondrial transcription is initiated from one of two promoters
on the H-strand (HSP1 and HSP2) and from a single promoter on the
L-strand (LSP) (Fig. 1). Transcription fromHSP2, located close to the 5′
end of the MT-RNR1 gene, and from LSP, situated in the D-loop,
generates almost genome-length polycistronic transcripts, which are
processed to produce the individual mRNA and tRNA molecules
[31,32]. HSP1 is located upstream of the MT-TF gene and produces
only the two rRNAs, 12S and 16S, and the two mt-tRNAs, mt-tRNAPhe
and mt-tRNAVal. The basal transcription machinery consists of a
limited number of nuclear-encoded proteins: the dedicated mito-
chondrial RNA polymerase (POLRMT), the transcription activator
TFAM, the transcription factor TFB2M (but probably not TFB1M as
previously thought [33,34]), and the termination factor mTERF [35].
In-depth reviews on mtDNA transcription are available [36,37].
Our current understanding of the mechanistic details of human
mitochondrial translation is far from complete. It is known to involve
nuclear-encoded factors imported into the organelle. Besides ribo-
somal proteins, aminoacyl synthetases, and mt-tRNA modiﬁcation
proteins, these include two mitochondrial initiation factors (IF2 and
IF3) [38,39], four mitochondrial elongation factors (EFG1, EFG2, EFTs,
and EFTu) [40–42], and at least one termination release factor, mtRF1a
[43]. Other recently identiﬁed nuclear-encoded factors are the
translation regulator PTCD3 [44], the ribosome recycling factor
mtRRF [45,46], and the methionine aminopeptidase MAP1D, which
removes N-terminal methionines [47]. Mitochondrial translation is
characterised by a number of distinct features including RNA-poor
mitoribosomes [48], bicistronic transcripts [49], partial stop codons in
some of the transcripts that are completed by polyadenylation [31,50],
and deviation from the standard genetic code.
3. Clinical features of human mtDNA disease
The mitochondrial genome has a very high mutation rate, 10- to
17-fold higher than that observed in nuclear DNA. Although mtDNA
repair systems do exist [51,52], they are not sufﬁcient to counteract
the oxidative damage sustained by the mitochondrial genome due to
its proximity to the RC complexes in the IMM and the ROS they
generate. Protective histones are also lacking.
Most mtDNA alterations are neutral polymorphisms, which have
proved useful in tracking human migrations [53]. The ﬁrst pathogenic
mtDNA mutations were identiﬁed in 1988 [54,55]. Since then, over
250 pathogenic mtDNA mutations (point mutations and rearrange-
ments) have been characterised [56], shown to cause a wide variety of
diseases with a heterogeneity of phenotypes and a variable age of
onset [57]. The exact prevalence of mtDNA disease is notoriously
difﬁcult to ascertain due to clinical heterogeneity of mitochondrial
diseases and the plethora of known causative mutations. Estimates
from the North East of England suggest that as many as 1 in 10,000
people have clinically manifesting mtDNA disease with a further 1 in
6000 at risk [58]. Recent birth prevalence studies have reported
mutation frequencies of 0.14% for the m.3243ANG mutation [59] and
∼0.2% for the m.1555ANG MT-RNR1 mutation associated withaminoglycoside-induced sensorineural hearing loss [60,61], suggest-
ing the perceived prevalence of mtDNA mutations remains an
underestimate.
A complete description of all known pathogenic mtDNAmutations
is beyond the scope of this review and a current compendium can be
found on the MitoMAP database [56]. Salient features of mtDNA
disease and their most common causative mutations (Fig. 2) will be
described.
3.1. Speciﬁc features of mitochondrial disease
The onset of clinical symptoms, phenotypic variability, and
variable penetrance of mitochondrial diseases are governed by a
number of factors, including the threshold effect, mitotic segregation,
clonal expansion, and a genetic bottleneck.
3.1.1. Threshold effect
Some deleterious mtDNA mutations are homoplasmic; however,
the vast majority are found in some but not all genomes. In the
presence of heteroplasmy, the ratio of wild-type to mutant mtDNA
determines the onset of clinical symptoms. A minimum critical
proportion of mutated mtDNAs is necessary before biochemical
defects and tissue dysfunction become apparent. This threshold
level varies for each mutation and differs amongst tissues, being
lower in tissues highly dependent on OXPHOS metabolism than in
tissues that can rely on anaerobic glycolysis. Typically, the threshold
value is in the range of 60%–90% mutant to wild-type mtDNA.
Although the threshold level can partly explain the disease pheno-
types observed in patients, an exact correlation between clinical
severity and the proportion of mtDNA mutation is lacking [62].
3.1.2. Mitotic segregation
During mitosis, mitochondria are randomly segregated, and in
heteroplasmic cells, the proportion of mutant mtDNA in the daughter
cells can thus shift. Should the mutant load exceed the pathogenic
threshold for that tissue, clinical expression of the disease can occur.
Conversely, mutant mtDNA may be lost, particularly in fast-dividing
tissues. For example, an average annual 1% decrease in m.3243ANG
mutation levels in blood has been described [63].
3.1.3. Clonal expansion
Clonal expansion refers to the preferential ampliﬁcation of mtDNA
mutations to a high level in post-mitotic tissues [64,65]. This
expansion is thought to be a result of random genetic drift, dependent
on relaxed replication of the mitochondrial genome [66].
3.1.4. MtDNA bottleneck
The observation of a rapid segregation in mammalian hetero-
plasmic mtDNA genotypes between generations, with a return to
homoplasmy in some progeny, has suggested the existence of a
mtDNA bottleneck during development [67–72]. The precise mech-
anism by which this genetic bottleneck occurs is currently being
ﬁercely debated. A prevalent hypothesis is that the bottleneck occurs
during embryonic development, driven by a marked reduction in
mtDNA copy number in the germ line [73,74]. Paradoxically, it has
also been suggested that the bottleneck occurs without reduction of
germ line mtDNA copy number, but is a result of the preferential
replication of a subgroup of mtDNAs during oogenesis [75]. Finally, a
third alternate view on the genetic bottleneck has recently been
proposed [76]. From observing the variations in mtDNA heteroplasmy
and copy number that occur throughout oogenesis in single germ
cells, it would seem the genetic bottleneck may actually take place
during postnatal folliculogenesis and not during embryonic oogenesis,
as a result of replication of a subpopulation of mitochondrial genomes.
Further investigations are necessary to clarify the exact nature of the
mtDNA bottleneck.
Fig. 2. Genotype:phenotype correlations in human mitochondrial disease. The circular, double-stranded human mitochondrial genome is depicted with sites of common mtDNA
mutations highlighted. Additionally, two further mtDNA point mutations described in this review, m.1624CNT [77] and m.5545CNT [83], are shown. Associated clinical
presentations are also highlighted. CPEO, chronic progressive external ophthalmoplegia; LHON, Leber hereditary optic neuropathy; LS, Leigh syndrome; MELAS, mitochondrial
myopathy, encephalopathy, lactic acidosis, and stroke-like episodes; MERRF, myoclonic epilepsy and ragged red ﬁbres; MILS, maternally inherited Leigh syndrome; NARP,
neurogenic weakness, ataxia, and retinitis pigmentosa; PS, Pearson syndrome.
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3.2.1. Point mutations
MtDNA point mutations are usually maternally inherited. They
may occur within protein, tRNA, or rRNA genes. However, more than
half of disease-related point mutations reported are located within
mt-tRNA genes. Phenotypically, point mutations in mitochondrial
protein-coding genes speciﬁcally affect the function of the RC complex
to which the corresponding protein belongs, whereas mt-tRNA
mutations may impair overall mitochondrial translation by reducing
the availability of functional mt-tRNAs.
Point mutations are mostly heteroplasmic, displaying considerable
clinical heterogeneity, and are considered highly recessive. However,
an increasing number of pathogenic homoplasmic mutations, often
affecting just a single tissue and characterised by incomplete
penetrance, are being recognised [77–82]. Given the high mutational
rate of the mitochondrial genome and the presence of numerous
family- or population-speciﬁc polymorphisms, the distinction be-
tween neutral mtDNA variant and disease-causing mutation can often
be difﬁcult. To complicate matters further, a dominant mt-tRNA
mutation, m.5545CNT in theMT-TW gene, was recently reported with
levels of mutation at b25% in clinically affected tissues [83]. Also, it has
been frequently recognised that certain nucleotide changes that are
not pathogenic per se may modulate the effects of deleterious mtDNA
mutations [84,85].
3.2.2. MtDNA rearrangements
The majority of mtDNA rearrangement mutations are large-scale
deletions, which vary in size from 1.3 to 8 kb and span several genes
[86]. Single mtDNA deletions occur sporadically early in develop-
ment, and the identical deletion is present in all cells within affectedtissues [87]. The occurrence of multiple mtDNA deletions of varying
lengths in affected tissues may be due to inherited mutations in
nuclear genes, whose products are involved in mtDNA maintenance
and replication (e.g., POLG and PEO1 encoding Twinkle) and
mitochondrial nucleotide metabolism (e.g., SLC25A4) [88–90]. An
exponential accumulation of multiple mtDNA deletions has also been
reported in aged postmitotic tissues and individuals with neurode-
generative diseases [91–93].
Despite different origins, most mtDNA deletions share common
features. Theymainly occur between the origins of replication, OH and
OL, and are typically ﬂanked by short direct repeats [94,95]. Their
mechanism of generation is also thought to be identical, irrespective
of the clinical phenotype [96], although the exact method by which
deletions are formed is currently under debate. Whilst most
researchers consider replication to be the most likely mechanism of
deletion formation [97], Krishnan et al. [98] recently proposed that
mtDNA deletions arise during the repair of damaged mtDNA.
The amount and tissue distribution of the deleted mtDNA are the
most important factors in determining clinical symptoms, and not, as
one might expect, the size and location of the deletions [99–101].
3.3. Clinical syndromes
The clinical syndromes associated with mtDNA mutations are
extremely variable and patients can present at any stage in life. On the
whole, the age of onset reﬂects the level of mutation and the severity
of the biochemical defect, but other factors (presumably nuclear
genetic or environmental) also effect the expression of disease. For
the purposes of this review, we will concentrate solely on primary
mtDNA diseases, the most common of which are depicted in Fig. 2,
together with their associated mutations. It should be noted that
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mutations in ageing, neurodegeneration, and tumourigenesis. How-
ever, an in-depth review of the role of mitochondrial mutations in
these diseases is beyond the remit of this article. For excellent recent
reviews on these topics, see references [102–104].
3.3.1. Mitochondrial diseases with onset in early infancy/childhood
3.3.1.1. Leigh syndrome. Leigh syndrome is a progressive neurode-
generative condition, which particularly affects the brainstem, dien-
cephalon, and basal ganglia. There are characteristic neuropathological
features, but newer neuroimaging techniques can now easily detect
these lesions in life. Clinically, these infants and children have signs of
brainstem and basal ganglia dysfunction and often deteriorate in a
stepwise manner. Leigh syndrome is due to severe failure of oxidative
metabolism and can be due to a variety of different genetic defects
affecting either the mitochondrial (e.g., m.8993TNC/G, m.10158TNC,
m.10191TNC) or nuclear genome (e.g., SURF1 gene) [105].
3.3.1.2. Depletion syndromes. The clinical features associated with
depletion syndromes depend upon the organ(s) which have mtDNA
depletion. On the whole, these are severe disorders and present in
childhoodwith severemuscle weakness, progressive encephalopathy,
or liver failure. There are a number of different genetic defects
identiﬁed in these patients and the clinical syndromes often reﬂect
the genetic defect [106]. In view of the tissue-speciﬁc nature of the
defect, these patients may respond to organ transplantation.
3.3.1.3. Kearns–Sayre syndrome (KSS). KSS is associated with the
development of retinitis pigmentosa and progressive external
ophthalmoplegia occurring before the age of twenty. Clinical
examination usually detects a ‘salt and pepper’ retinopathy of the
posterior fundus without the visual ﬁeld defects, optic disk pallor, and
attenuation of retinal vessels usually seen in retinitis pigmentosa. KSS
is a multisystem disorder caused by single, large-scale deletions [107].
Patients often develop other neurological complications including
cerebellar ataxia, cognitive impairment and deafness, as well as non-
neurological features of cardiomyopathy, complete heart block,
deafness, short stature, endocrinopathies, and dysphagia.
3.3.1.4. Pearson syndrome. This is a rare disorder of infancy
characterised by sideroblastic anaemia with pancytopaenia and
exocrine pancreatic failure. The clinical course in these children can
be severe leading to early death. In those that survive the blood
disorder improves but they later develop the clinical features of KSS.
In these children, there is a very high level of large-scale singlemtDNA
deletion present in all tissues [108].
3.3.2. Mitochondrial diseases with onset in late childhood or adult life
3.3.2.1. Mitochondrial encephalopathy, lactic acidosis, and stroke-like
episodes (MELAS). These patients often present with stroke-like
episodes with seizures. They particularly affect the parieto-occipital
region of the brain leading to visual ﬁeld defects. Their lesions do not
match a recognised vascular distribution, highlighting that they are
not simple ischemic lesions. Seizures are frequent in these patients
associated with the episode or as isolated phenomena. Other features
include intermittent episodes of encephalopathy, vomiting, migraine
like headaches, ataxia, and cognitive impairment. Over 80% of patients
with MELAS have the m.3243ANG mutation in the MT-TL1 gene
[109,110]. Other mutations in this mt-tRNA gene (e.g., m.3271TNC)
[111], other mt-tRNA genes (e.g., m.1642GNA,MT-TV gene) [112] and
protein-encoding genes (e.g., m.9957TNC in the MT-CO3 gene [113],
several MT-ND5 mutations (m.12770A NG, m.13045A NC,
m.13513GNA and m.13514ANG) [114–117] and MT-ND1 mutations
[118]) may also cause MELAS.3.3.2.2. Chronic progressive external ophthalmoplegia (CPEO). One of
the most common presentations of mtDNA disease in adults is CPEO.
CPEO is characterised by a progressive paralysis of the eye muscles
leading to impaired eye movement and ptosis. Ptosis is frequently the
presenting symptom and may be asymmetrical; however, patients
usually progress to bilateral disease. CPEO is typically caused by
sporadic large-scale single deletions or multiple mtDNA deletions
[119,120], although mtDNA point mutations are detected in some
patients (e.g., m.3243ANG [121], m.12316GNA [122]). In patients
with CPEO, there may be other features depending on the underlying
genetic defect but myopathy and fatigue are common in all patients.
3.3.2.3. Neuropathy, ataxia, and retinitis pigmentosa (NARP). This
combination of symptoms has been described in several families and
is usually due to the MT-ATP6 m.8993TNG mutation. Although
peripheral neuropathy is the principle feature of this phenotype
other neurological complications include developmental delay,
seizures, and dementia. It has subsequently been recognised that
patients with a mutant load greater than 95% m.8993TNG have an
onset in childhood with maternally inherited Leigh syndrome (MILS)
[123]. This reﬂects the importance of the degree of heteroplasmy
inﬂuencing the phenotype, at least with this mtDNA mutation.
3.3.2.4. Leber's hereditary optic neuropathy (LHON). There are three
primary LHON mtDNA mutations (m.11778GNA, m.3460GNA, and
m.14484TNC), which in total are present in at least 95% of LHON cases
[56,124]. LHON is predominantly an organ-speciﬁc disease, targeting
the retinal ganglion cells of the optic nerve. Clinically, this presents
with a subacute or acute, painless, central visual loss, which is
typically unilateral with the other eye usually becoming affected
within the next 2 months. This visual loss usually occurs between the
ages of 20 and 40 and is more common in men. LHON is usually due to
a homoplasmic mtDNA mutation and all maternal offspring will
inherit the mutation; however, whilst 50% of males will be affected,
only 10% of females will develop visual loss. The progression of the
disease seems to depend upon the responsible mutation with 71% of
patients with the m.14484TNC mutation showing some recovery,
compared to 25% with m.11778GNA [125]. Whilst the majority of
patients withm.11778ANGwho have symptoms develop LHON, there
have been a few reports of other neurodegenerative phenotypes
including early-onset dystonia [80].
3.3.2.5. Myoclonic epilepsy and ragged red ﬁbres (MERRF). MERRF is
a progressive, neurodegenerative disease causedmost commonly by a
point mutation in the MT-TK gene, m.8344ANG [126–128]. Clinically,
MERRF is a severe neurodegenerative disorder, which often presents
in childhood or early adulthood following normal development. The
characteristic myoclonus is often the presenting symptom. This
progresses into a mixed picture of myopathy, often with pronounced
proximal muscle wasting in a limb-girdle distribution, and central
neurological features of focal and generalised epilepsy, cerebellar
ataxia, optic atrophy, pyramidal signs, and hearing loss. Non-
neurological manifestations include re-entrant atrioventricular tachy-
cardias such as Wolff–Parkinson–White syndrome and multiple
lipomas.
4. Diagnosis of mtDNA disease
Complicated by mtDNA heteroplasmy, the lack of clear genotype:
phenotype correlations in many patients and the complex interac-
tions between the nuclear and mitochondrial genome, the laboratory
diagnosis of mtDNA disease often involves piecing together informa-
tion from clinical, histochemical, and biochemical testing to inform
molecular testing, allowing the development of rational diagnostic
algorithms [129,130]. Family history and characteristic, histological
changes in affected tissues are key signs that may prompt the
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evident. Deﬁning whether the primary molecular defect resides
within the mitochondrial genome itself (single, large-scale mtDNA
rearrangement or mtDNA point mutation) or in a nuclear gene—
leading to secondary mtDNA abnormalities such as loss of mtDNA
copy number or multiple mtDNA deletions—ultimately provides key
information to families and clinicians concerning likely inheritance
patterns, recurrence risks, and disease prognosis. Whilst by no means
exhaustive, this short section provides a summary of the key
histochemical and molecular approaches to making a mitochondrial
genetic diagnosis.
4.1. Histochemical and biochemical testing
Many, but not all, patients with mtDNA disease show histological
and histochemical changes in affected tissue, indicative of RC
dysfunction. Classically, these are ragged red ﬁbres—so called
because of the appearance of ﬁbres on Gomori trichrome staining
showing subsarcolemmal accumulation of abnormal mitochondria—
and cytochrome c oxidase (COX)-deﬁcient ﬁbres (Fig. 3). The COX
enzyme contains subunits encoded for by both the mitochondrial
and nuclear genome, and as such, a mosaic pattern of COX activity—
where the COX-deﬁcient ﬁbres may also be “ragged red”—is highly
suggestive of mtDNA involvement. There are notable exceptions to
this rule; biopsies from patients with the MELAS phenotype and/or
mutations in complex I and complex III mtDNA-encoded subunits
may be normal or exhibit COX-positive ragged red ﬁbres. A global
decrease in the activity of COX is usually suggestive of a nuclear
mutation in an ancillary protein required for COX assembly such as
SURF1 but can be associated with some homoplasmic mt-tRNA
defects [77,78]. The sequential reaction of COX and SDH histo-
chemical activities is helpful to identify low levels of COX-deﬁcient
ﬁbres, although care must be made in the interpretation of these as
the somatic accumulation of mtDNA mutation with age also leads to
focal, COX-deﬁcient ﬁbres in muscle and other postmitotic tissues.
Biochemical testing of clinically affected tissue will often involve the
determination of individual RC enzyme complex activities in
mitochondrial fractions or enriched homogenates prepared from
fresh or frozen tissue samples [131]; some labs also investigate
functional testing of intact organelles to include measurements of
mitochondrial substrate oxidation, oxygen consumption, and ATP
synthesis [132]. The identiﬁcation of isolated or multiple RC
abnormalities further narrows the options for identifying the
molecular genetic defect.
4.2. Molecular genetic testing
Diagnostic algorithms and protocols are available for the molec-
ular investigation of patients with suspected mtDNA disease
[130,133,134]. Some mutations—mtDNA rearrangements and certainFig. 3. Histopathological abnormalities associated with mtDNA disease. The histological and
muscle—provides useful clues in the laboratory diagnosis of mtDNA disease. Two ﬁbres (high
from a patient with a single, large-scale mtDNA deletion highlighting the following stains o
stain highlighting classical ragged red muscle ﬁbres; c, SDH, which reveals the subsarcolemm
histochemistry showing COX-deﬁcient ﬁbres within a population of normal ﬁbres, a typica
COX-deﬁcient ﬁbres which retain SDH activity.mtDNA point mutations—are only present in clinically affected
tissues, necessitating the work-up on postmitotic (muscle) DNA
samples. MtDNA rearrangements (deletions and duplications) have
historically been assessed by Southern blotting [54], although long-
range PCR is now often themethod of choice. The presence of multiple
mtDNA deletions would indicate the screening of appropriate nuclear
mtDNA maintenance genes including POLG, POLG2, SLC25A4, PEO1,
and OPA1 [135]; the demonstration of a quantitative loss of mtDNA—
usually by real-time PCR with reference to a nuclear housekeeping
gene—is indicative of a recessive mtDNA depletion disorder; several
known genes are now implicated, leading to either a myopathic or
hepatocerebral phenotype [106].
Common mtDNA point mutations (m.3243ANG, m.8344ANG,
m.8993TNG/C, and LHON mutations) are readily screened in blood
using restriction fragment length polymorphism (RFLP) analysis, with
the addition of a radio- or ﬂuorescent label in the ﬁnal PCR cycle to
permit accurate quantiﬁcation of mtDNA heteroplasmy; however, the
m.3243ANG mutation is positively selected against in this tissue,
prompting the investigation of other noninvasive tissue samples for
diagnosis [136,137]. The assessment of m.3243ANG mutation load in
urinary sediments not only provides a correlate with the level in
muscle but also has proven to be an accurate indicator of clinical
outcome for these patients [138].
Due to its small size, screening the entire mitochondrial genome
can be undertaken relatively easily to identify rare or novel mtDNA
mutations in patients with suspected mtDNA disease. Denaturing
gradient gel electrophoresis (DGGE) [139,140] and denaturing high-
performance liquid chromatography (dHPLC) [141,142] have been
available for some years, whilst emerging technologies include
resequencing microarrays such as the Affymetrix MitoChip 2.0
[143,144]. Many laboratories, however, continue to directly sequence
the entire mitochondrial genome in affected tissues, using over-
lapping primer sets to ensure complete coverage of the 16.6 kb
genome [145]. Given the highly polymorphic nature of the mito-
chondrial genome, careful assessment of newly identiﬁed mtDNA
sequence variants must be undertaken to establish a clear link with
human disease. A number of canonical criteria to support pathoge-
nicity for a novel mtDNA variant, originally proposed by DiMauro and
Schon [146] and applied by others [147,148], should be considered
(Fig. 4) and a pathogenic role only assigned once sufﬁcient evidence is
available [149].
5. Functional characterisation of mtDNA mutations
Pathogenic mtDNA mutations invariably result in a general defect
in mitochondrial respiration that leads to a reduced ability to produce
cellular ATP. The clinical phenotypes of mitochondrial disorders are
however extremely heterogeneous. Consequently, it is unlikely that a
reduced respiration rate is solely responsible for this variability, but
rather additional molecular mechanisms must also contribute to thehistochemical assessment of clinically affected tissue—often but not exclusively skeletal
lighted by an asterisk) are shown in this sequential series of transverse muscle sections
r activities; a, H&E to show general muscle morphology; b, modiﬁed Gomori trichome
al accumulation of mitochondrial activity, is exclusively found in mitochondria; d, COX
l “mosaic” distribution; e, sequential COX/SDH histochemistry highlighting individual
Fig. 4. Determination of mtDNA mutation pathogenicity. a, Accepted canonical criteria for assigning pathogenicity to novel mtDNA mutations. b, Example of the segregation of a
speciﬁc mtDNA point mutation, m.15967GNA, with biochemical deﬁciency in individual cells as a tool for assigning pathogenicity. Graphical representation of single muscle ﬁbre
polymerase chain reaction data demonstrate a clear segregation of high mutation load in the COX-deﬁcient muscle ﬁbres [256]. c, Example of an mt-tRNA functional defect. High-
resolution Northern blot of patient (P) and control (C) muscle total RNA demonstrates signiﬁcantly reduced steady-state levels of mutated mt-tRNAVal harbouring the m.1624CNT
mutation.
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and develop effective therapeutic approaches for mitochondrial
disorders, it is important to uncover the biochemical and molecular
mechanisms linking genotype to phenotype. Identiﬁcation of the
diverse functional effects of mtDNA mutations has proved challeng-
ing. Firstly, engineering mtDNA is problematic due to its polyploidy,
inaccessibility within a double-membraned organelle, and apparent
lack of, or minimal, recombination, which have prevented the
successful transfection of autonomously replicating foreign DNA
plasmids or modiﬁed mtDNA into mitochondria to date. Secondly,
the development of suitable models of disease that accurately portray
the pathogenesis of mitochondrial diseases has been quite slow. Only
very recently has a naturally occurring canine model of mitochondrial
disease been reported. A single heteroplasmic mt-tRNATyr deletion
(m.5304delT of dog mtDNA) has been found to be responsible for the
neurological disorder sensory ataxic neuropathy in golden retrievers
[150]. Whilst no human equivalent of this mutation has yet been
identiﬁed, the model may be of use in the development of therapeutic
approaches for human mitochondrial diseases.
Despite these difﬁculties, considerable progress has been made
over the last few years in understanding themolecular mechanisms of
mitochondrial disease. The experimental models that have enabled
these developments will ﬁrst be discussed, followed by the current
understanding of mitochondrial pathogenesis.
5.1. Experimental models of mitochondrial disease
5.1.1. Transmitochondrial cybrids
In vitro models of mitochondrial disease are achieved through
fusion of enucleated cytoplasts (derived from patient cell lines) withimmortalised human cell lines, devoid of endogenous mtDNA (ρ0
cells). Following pioneering work by Morais and colleagues between
1985 and 1988 establishing avian ρ0 cells [151,152], the ﬁrst
transmitochondrial cytoplasmic hybrid cells (cybrids) using human
ρ0 cells were described in 1989 [153]. Cybrids have since proved an
excellent tool for studying mtDNA mutations. By allowing selected
mtDNA sequences to be expressed against ﬁxed nuclear backgrounds,
not only can cybrids be employed for establishing and/or conﬁrming
the genetic origin of a mitochondrial disorder, but they can also
provide a controlled environment in which to study both the
functional and physiological consequences of varying levels of
heteroplasmy of speciﬁc mtDNA mutations as well as the precise
molecular mechanisms by which these mutations impair cellular
function. In addition, these cell models have challenged our
established criteria for pathogenicity with the identiﬁcation of the
ﬁrst mt-tRNA suppressor mutation, m.12300GNA inMT-L2 [154], and
the ﬁrst functionally dominant mt-tRNAmutation, m.5545CNT inMT-
TW [155]. For further details on the history, development and use of
cybrids for the study of mtDNA mutations see Khan et al. [155] and
Swerdlow [156].
Precautions are necessary when extrapolating from the cybrid
system. Most cybrid models are generated using aneuploid tumour
cells. The effects of aneuploidy on mitochondrial function are not
clear; however, it is reasonable to assume that it can affect the
stoichiometry of nuclear- and mitochondrial-encoded RC subunits,
thus interfering with genotype–phenotype relationships. On a similar
note, tumour cells are largely glycolysis-dependent, relying little on
OXPHOS for generating the majority of their energy requirements. In
contrast, mtDNA disorders typically occur in highly aerobic cells. It is
important to consider what impact, if any, the primary energy
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expression of an mtDNA mutation [156].
It is also important to note that both the ρ0 and cybridisation
processes can impact strongly on the cellular transcriptome. Indeed,
microarray studies have demonstrated that both processes can cause
signiﬁcant and stable up-regulation of many nuclear transcripts
involved in OXHOS, even after repopulation of ρ0 cells with wild-type
mitochondria [157,158]. These observations might in part explain
why in vivo phenotypes are not always replicated in an in vitro cybrid
system. For example, cybrids harbouring the homoplasmic MT-TV
m.1624CNT mutation, which caused a profound metabolic defect in
skeletal and cardiac muscle, with low complex I and IV activities, and
resulted in multiple neonatal deaths [159], were found to lack the
marked respiratory defect despite retaining a striking reduction inmt-
tRNAVal steady-state levels [159].
5.1.2. Yeast models
Because the manipulation of the mammalian mitochondrial
genome has proved frustratingly problematic, a number of research-
ers have turned to yeast as an alternative model system for the
investigation of mtDNA mutations. Saccharomyces cerevisiae is
currently the only known organism in which mitochondrial genetic
transformation is possible. Most importantly, this can be achieved in a
highly controlled fashion as DNA delivered to mitochondria via
biolistic transformation can only incorporate into the mitochondrial
genome by homologous recombination [160]. Thus, it is possible to
introduce mutations at any desired position in yeast mtDNA genes.
Recently, the biochemical consequences of a mutation in the protein-
coding gene, MT-ATP6 (m.8993TNC), have been investigated in yeast
[161]. Moreover, given the sequence and structural similarities of
some human and yeast mt-tRNAs, this in vivo system is particularly
interesting for modelling mt-tRNA mutations equivalent to human
pathogenic base substitutions [162–164]. Furthermore, in view of the
ability of S. cerevisiae to survive in the complete absence of functional
mtDNA, the study of very severe mitochondrial defects is possible.
To date, yeast models have been successfully employed in the
identiﬁcation of mt-tRNA mutation suppressors. Overexpression of
both the mitochondrial translation elongation factor EFTu [162] and
the mitochondrial leucyl-tRNA synthetase [163] has been reported to
rescue mitochondrial dysfunction caused by the yeast equivalents of
the m.3243ANG, m.3256CNT, and m.3291TNC MELAS mutations.
Similar abilities for EFTu in human myoblasts harbouring the
m.3243ANG mutation [165] and leucyl-tRNA synthetase in transmi-
tochondrial WS277.546 human cell lines also containing the
m.3243ANG mutation [166] have since been described.
Signiﬁcant time and effort have been invested in validating the
yeast model system for the investigation of human pathogenic
mutations [162,164,167]. Nonetheless, several limitations do hamper
the more widespread use of this organism as a model system of
mitochondrial disorders. Not all human mt-tRNAs share strong
homology with yeast mt-tRNAs. Also, S. cerevisiae are inherently
homoplasmic, thus precluding threshold studies, although it is
possible to modulate the severity of yeast respiratory phenotypes by
studying mt-tRNA mutations in different nuclear contexts [163,164].
Finally, fermentative yeast such as S. cerevisiae lack complex I.
However, the introduction over the past decade of an alternative
model, the obligate aerobic yeast Yarrowia lipolytica, which possesses
a vital proton-pumping NADH:ubiquinone oxidoreductase, has
enabled important structural and functional analyses of mitochon-
drial complex I [168].
5.1.3. Mouse models
Whilst cybrids and yeast have helped to further our current
understanding of mitochondrial genetics and the molecular mechan-
isms of disease, a mammalian in vivo model system is ultimately
necessary for answering the many questions regarding mtDNAbiology, mitochondrial disease pathogenesis and tissue speciﬁcity
that still remain. For example, how can one mutation, such as
m.3243ANG or m.8993TNC, result in multiple phenotypes (MELAS
and MIDD, or NARP and MILS, respectively)? If all mtDNA mutations
result in ATP deﬁciency, why are there so many different disease
phenotypes?Why are somemetabolically active tissuesmore affected
than others?
Due to their rapid life cycle, ease of propagation, well-described
genetics, and long-standing use in biological research, mice have
become an important model system for understanding mitochondrial
pathology. As it is not possible to directly manipulate their
mitochondrial genome, researchers have been forced to adopt more
ingenious and indirect ways of engineering mouse mtDNA.
The ﬁrst heteroplasmicmicewere generated by cytoplasmic fusion
of two normal mouse strains carrying distinct haplotypes [74,169].
These mice harboured only polymorphic mtDNA variants. However,
the repeated observation of directional selection for one mtDNA
genotype in certain tissues [170], mediated by single tissue-speciﬁc
factors [171], suggests these mouse models will be particularly
important in our quest to understanding the basis of tissue speciﬁcity
and mtDNA somatic segregation.
Additional transmitochondrial mouse models, showing signs of
mitochondrial dysfunction and capable of transmitting mtDNA
mutations to subsequent generations, have since been established,
including the ‘Mito-mice’ model that harbours high levels of a single
heteroplasmic mtDNA deletion and shows a multitude of symptoms
including myopathy, cardiomyopathy, renal failure, anaemia, deaf-
ness, lactic acidosis, a mosaic pattern of COX deﬁciency, and a
shortened life-span [172,173]. The ‘Mito-mice’ phenotype closely
mimics that of early-onset Pearson syndrome, which is caused by a
single heteroplasmic mtDNA deletion resulting in anaemia, myopa-
thy, and pancreatic and renal insufﬁciency. Recently, transmitochon-
drial mouse models of mtDNA point mutations have been generated.
Two heteroplasmic point mutations introduced in MT-ND6
(m.13885insC) and MT-CO1 (m.6589TNC) resulted in myopathy and
cardiomyopathy [174], and the injection of m.3243ANG mutated
mitochondria into C57BL/6J mouse zygotes led to respiratory
dysfunction and enhanced ROS production in heteroplasmic tissues
[175].
Alternative and more successful approaches to developing mouse
models of mitochondrial disease involve manipulating the nuclear
genes that regulate mtDNA maintenance and replication, such as
TFAM [176–182], POLG (‘Mutator’ model) [183], and PEO1 (Twinkle;
‘Deletor’ model) [184]. However, these models are beyond the scope
of the current review; for further details see Vempati et al. [185] and
Tyynismaa and Suomalainen [186].
5.2. Molecular mechanisms of mitochondrial disease
On account of the gradual development of these various
experimental models, our understanding of the functional conse-
quences of mtDNA mutations and the molecular mechanisms by
which mitochondrial diseases develop is progressing. Biochemical
effects of mtDNA mutations have been well described in all
experimental systems and are invariably characterised by lower
cellular respiration, compromised RC complex activity, and reduced
ATP synthesis. Due to the role of mitochondria in the generation of
ROS and the regulation of apoptotic cell death, the status of these
pathways in patient cell lines, tissues, and mouse models of disease
harbouring mtDNA mutations has been frequently investigated.
Depending on the experimental model used, conﬂicting results have
been observed. Increased ROS production has been described in
neuronal NT2 cybrid cells containing m.3460GNA and m.11778GNA
LHON mutations [187], in lymphocytes with m.8993TNC and
m.8993TNG NARP mutations [188] and more recently in the chimeric
m.3243ANG mice mentioned previously [175]. Conversely, normal
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eventually accumulate sufﬁcient mtDNA mutations to cause severe
OXPHOS deﬁciency [189]. Furthermore, no increase in programmed
cell death was identiﬁed in this mouse model, contrary to a double
TFAM knockout mouse model in which substantial apoptosis occurred
at embryonic day 9.5 [179,190].
5.2.1. Molecular impacts of mt-tRNA mutations
So far, investigations into the molecular mechanisms of mtDNA
mutations have mainly concentrated on elucidating the molecular
impacts of mt-tRNA mutations, in particular determining the
structural and/or functional perturbations capable of interfering
with mitochondrial protein synthesis. Transmitochondrial cybrids
have proved instrumental in studying the variousmt-tRNAmutations.
In vitro transcribed wild-type and mutated mt-tRNAs have also been
used.
Mt-tRNAs are characterised by a distinctive cloverleaf-shaped
structure, maintained in part by Watson–Crick base pairing, and thus
consist of four domains: an acceptor stem, a dihydrouridine (DHU)
stem/loop, a TψC-stem/loop and an anticodon stem/loop. This
secondary structure is further condensed into an L-shaped form
through conserved tertiary interactions. The fundamental function of
mt-tRNA molecules is to enable mitochondrial protein synthesis by
the ribosome. Their ability to carry out this function is critically
dependent on the appropriate processing of the primary polycistronic
transcript into mature mt-tRNA as well as the adoption of the
appropriate 3D structure.
Mutations have been found to affect all aspects of mt-tRNA
biogenesis. Correct transcription of 16S mt-rRNA is impaired by the
common mt-tRNALeu(UUR) m.3243ANG mutation, which interferes
with a transcription termination site located at the boundary of the
16S mt-rRNA and mt-tRNALeu(UUR) genes, causing accumulation of an
unprocessed RNA intermediate (RNA19) including 16S mt-rRNA, mt-
tRNALeu(UUR) and MTND1 [191–193]. Following transcription, endo-
nucleolytic 5′- and 3′-end cleavage of precursor mt-tRNA molecules
and subsequent 3′-CCA addition are necessary to produce mature mt-
tRNAs. Mt-tRNALeu(UUR) mutations m.3256CNT, m.3260ANT and
m.3271TNC lead to impaired RNase P processing of 5′-leader
sequences in vitro [194], whilst the mt-tRNASer(UCN) m.7445TNC
transition reduces the efﬁciency of 3′-cleavage [195]. Mt-tRNA
structural stability and the presence of recognition elements for
interacting protein factors are achieved by post-transcriptional
modiﬁcation of mature transcripts (e.g., methylation, 5-taurimo-
methyluridine modiﬁcation). Interestingly, m.3243ANG has been
shown to impair methylation of mt-tRNALeu(UUR) in cybrid osteosar-
coma cells [196], but to prevent taurine modiﬁcation of the anticodon
wobble position (U34) in cybrid HeLa cells [197]. Similarly, post-
transcriptional modiﬁcations of mt-tRNALys m.8344ANG mutant
mt-tRNAs are also dependent on nuclear background [196,198].
Mt-tRNA mutations invariably result in structural defects, which
may range from mild to severe. The mt-tRNASer(UCN) m.7512TNC
mutation causes slight localised kinking of the acceptor stem [199],
whereas m.3243ANG, in the DHU stem, is responsible for a dramatic
structural change, which disrupts both the L-shaped tertiary fold
of mt-tRNALeu(UUR) by preventing np A14/U8 interaction [200] and
its quaternary structure by promoting the formation of a dimeric
complex by intermolecular D-loop base pairing [201]. Finally,
decreased mt-tRNA stability has been described with the m.8344ANG
mutation both in vitro and in cybrid osteosarcoma cells [198,202].
The functional properties of mt-tRNAs, such as their capacity for
aminoacylation and binding to various protein factors of the
mitochondrial translation machinery, may also be affected by mt-
tRNA mutations. Only mature and correctly folded mt-tRNAs can be
esteriﬁed by their cognate aminoacyl synthetase. Given the ease with
which mt-tRNA structure can be disrupted, numerous cases of
decreased mt-tRNA aminoacylation have been reported. Recentexamples include the mt-tRNAPhe m.611GNA mutation, which
decreases aminoacylation activity 100-fold in vitro [203], and the
mt-tRNATyr m.5874TNC and m.5877CNT transitions [204]. Following
aminoacylation, mt-tRNAs are transported, by transient binding to
translation factors (e.g., EFTu), to the ribosome, whereupon transfer of
the amino acid to the growing polypeptide chain completes protein
synthesis. By altering mt-tRNAIle T-stem structure, the mutation
m.4269ANG impairs binding afﬁnity for EFTu two-fold [205]. Formore
in-depth reviews of the effects of mutations onmt-tRNA structure and
function see references [206–208].
5.2.2. Global effects of mtDNA mutations
Whilst the direct investigations of mtDNA mutations have
revealed important molecular effects, it is becoming increasingly
apparent that new global approaches are required to fully elucidate
the molecular mechanisms of mtDNA mutations and to correlate
these mechanisms with the phenotypic expression of mitochondrial
diseases. Indeed, the constantly increasing numbers of causative
mutations, the absence of unifying mechanistic features, the inﬂuence
of the nuclear background on the mutation effects, and the increasing
realisation that mitochondrial proteins possess a dual cellular
localisation [209,210] make the use of the unbiased methodology of
modern post-genomic approaches particularly appealing for applica-
tion in the ﬁeld of mitochondrial research. The global transcriptomic
and comparative proteomic investigations performed to date to
determine the wide-ranging mitochondrial and cellular effects of
mtDNA mutations in the context of mitochondrial disorders are
outlined below.
Microarray analyses have been performed using a variety of
platforms, biological samples, and experimental designs, making
direct comparisons between experiments difﬁcult. Nonetheless, some
common transcriptional responses to mitochondrial dysfunction are
emerging. For example, genes involved in cellular metabolic path-
ways, such as the TCA cycle, energy production, and amino acid
metabolism, are reportedly up-regulated not only in patients with the
4977 bpmacrodeletion [211], but also in two lymphoblast cybrid cells
containing the LHON mutations m.3460GNA (in the MT-ND1 gene)
and m.11778GNA (MT-ND4 gene) [158], in a 143B osteosarcoma
cybrid cell line with the m.8993TNG NARP mutation (MT-ATP6 gene)
[212], and in muscle [211], neuronal cells [213] and 143B cybrid cells
[212,214] harbouring the m.3243ANG mutation.
Other shared transcriptional consequences of mitochondrial
dysfunction include inhibition of both ubiquitin-mediated protein
degradation and mitochondrial and nuclear ribosomal protein
synthesis [214,215], as well as activation of the unfolded protein
response [215,216]. An induction in the expression of several nuclear
RC transcripts has also been observed in macrodeleted muscle [211]
and in 143B cells harbouring the m.8993TNG NARP mutation [212].
This response has previously been reported in muscle with over 88%
levels of the m.3243ANG mutation [217], but it is also thought to
represent a sustained effect of the cybridisation process [158]. Nuclear
OXPHOS gene up-regulation may thus be considered a generic
compensatory effect for mitochondrial dysfunction.
Intriguingly, recent work published by Alemi et al. [215] does not
agree with many of these communal transcriptional responses. The
transcriptomes of muscle and six cybrid cell lines containing 4977 bp
and 7.5 kb mtDNA deletions revealed a reduction in the expression of
metabolic pathway genes and nuclear OXPHOS genes relative to
controls. Furthermore, the mtDNA deletions were shown to exert a
negative effect on cell proliferation and cell cycle. Similar ﬁndings
were also later reported in two ﬁbroblast cell lines harbouring the
microdeletion m.9205delTA in MT-ATP6 [218]. Why such discrepan-
cies exist is not clear but they may represent intrinsic differences
between cell types/tissue, varying levels of heteroplasmy or varia-
tions in experimental design. Moreover, the nature of the mtDNA
mutations, in particular the m.9205delTA deletion, which eliminates
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and causes a marked decrease in RNA14 (MT-ATP8 and -6-encoding
bicistronic transcript) steady-state levels [81], may account for these
disparate ﬁndings.
Whilst transcriptomic analyses can provide invaluable information
on the molecular mechanisms of disease, it is ultimately the effects on
protein expression (known to not always reﬂect transcriptional
ﬂuctuations) and their post-translational modiﬁcations that dictate
the phenotypic expressions of pathogenic mutations. The application
of proteomics to further our understanding of numerous human
diseases is well established. However, surprisingly few attempts to
proﬁle proteomic changes associated with primary mtDNA mutations
have been reported. A large-scale quantitative proteomic study to
investigate the effects of primary inherited mtDNA mutations on
mitochondrial proteins was performed in 2002 by Rabilloud et al.
[219]. Mitochondrial proteomes of wild-type and mutant cybrid cell
lines, harbouring either the m.8344ANG MERRF or m.3243ANG
MELAS mutations, were compared by silver-stained two-dimensional
electrophoresis (2-DE). A number of up- and down-regulated proteins
associated with both phenotypes were observed. In particular, the
expression levels of two proteins, both nuclear-encoded subunits of
CIV (Vb and VIa), were shown to be dramatically reduced in both
mutant cell lines relative to their sibling wild-type. Subsequently,
quantitative analysis of N800 total detectable spots revealed almost
5% with signiﬁcant quantitative variations in m.8344ANG mutant
cybrid cell lines versus control [220]. As would be expected, these
included the 13 mitochondrially encoded OXPHOS subunits [221–
223]. In addition, several nuclear-encoded mitochondrial proteins,
including RC subunits, metabolic enzymes and a mitochondrial
translation protein, were identiﬁed [220]. However, whilst these
initial results appeared promising, the study unfortunately did not
address the issue of aneuploidy inherent to cybrid cells.
To the best of our knowledge, this analysis remains the only
proteomic study to date to investigate the wider effects of speciﬁc
primary mtDNA defects. Recently, the global cellular proteomic
response of CRL-8303 osteosarcoma cells with chemically reduced
OXPHOS activity has been analysed by silver-stained 2-DE [224].
Inhibition of CI or CIV caused changes in the expression levels of
apoptotic, cytoskeletal, and OXPHOS proteins, as well as proteins
involved in TCA cycle, glycolysis, and oxidative stress responses.
Mostly, current efforts are concentrating on elucidating the complete
mammalian mitochondrial proteome, a critical step in furthering our
understanding of the role of mitochondria in health and disease
[209,225,226]. The most recent mammalian mitochondrial compen-
dium (MitoCarta) consists of 1098 identiﬁed proteins [209].
These preliminary transcriptomic and proteomic investigations
have proven to be useful approaches for mining new data and will
hopefully open new perspectives for understanding mitochondrial
disorders. Nonetheless, more global investigations are required to
fully appreciate and comprehend not only the diverse molecular
pathways that are dysregulated in the pathogenesis of mitochondrial
disease and contribute to the expression of the disease but also any
potential cellular compensatory effects to mitochondrial dysfunction.
Ultimately, these approaches, if correctly applied, offer a promising
strategy for the development of much-needed therapies.
6. Management of mtDNA disease
Despite considerable advances over the last decade in our
understanding of mitochondrial genetics and function and the
pathogenesis of mtDNA diseases, no effective treatment options are
currently available for patients with mitochondrial dysfunction,
except in rare cases where surgery or transplant may be indicated.
Given the complexities of mitochondrial genetics and the phenotypic
variability expressed in mtDNA disorders, the development of a
generic ‘cure’ for mitochondrial disorders has been problematic. Theadministration of various pharmacological and biochemical agents,
including vitamins, cofactors, metabolites, and electron acceptors, to
correct or bypass the underlying RC defect has met with limited
success (reviewed in [227]). Current focus is on developing mutation-
and disease-speciﬁc therapies to minimise symptoms and prevent
complications. Two main approaches are being actively pursued,
namely exercise and gene therapy. Signiﬁcant efforts are also being
made to prevent mtDNA disease transmission.
6.1. Exercise therapy
Management of mtDNA disease through exercise training aims to
improve physical capacity and quality of life in patients with high
levels of heteroplasmic mtDNA mutations in muscle. Well tolerated
and safe, endurance training for up to 14 weeks has been found to
improve OXPHOS function, although no concomitant shift in mutated
mtDNA levels in muscle has been observed and cessation in training
does cause a loss of the physiological adaptations [228–230]. Long-
term follow-up training studies are currently underway to determine
if changes in mtDNAmutation load are possible. Recently, the beneﬁts
of daily aerobic exercise have been further demonstrated in condi-
tionalCOX10 knockoutmice,which typically develop severemyopathy
at ∼2.5–3 months [231]. Muscle conditioning enhanced ATP levels,
delayed disease onset, and increased life expectancy in these mice.
Resistance exercise protocols have shown similar promise. This
approach is based on the stimulation of muscle regeneration in
response to ﬁbre injury. Undifferentiated myogenic cells, satellite
cells, are known to proliferate in response to damage caused by
concentric (shortening) or eccentric (lengthening) muscular contrac-
tions. In patients with high levels of sporadically mutated mtDNA in
mature muscle ﬁbres but with low or undetectable levels in satellite
cells, activation of these stem cells and subsequent incorporation of
wild-type satellite mtDNA into mature muscle may shift hetero-
plasmy levels sufﬁciently to recover muscular function (termed “gene
shifting”) [232]. Twelve-week resistance training studies in patients
with single, large-scale mtDNA deletions have been demonstrated to
increase satellite cell number with concomitant improvements in
muscular strength and oxidative capacity evidenced by a decrease in
the proportion of COX-negative ﬁbres [233]. Further work is required
to determine the optimal exercise regime parameters.
6.2. Gene therapy
On account of the peculiarities of mitochondrial genetics new and
inspired approaches to genetic-based strategies for mtDNA disease
therapy have been necessary. Manipulation of heteroplasmy levels to
shift the balance of mutant to wild-type genomes, critical in
determining the expression of the biochemical defect, has been
attempted by a number of different approaches. Antigenomic therapy,
which involves using sequence-speciﬁc nucleic acid derivatives that
selectively target and inhibit the replication of mutated mtDNA thus
allowing the wild-type genome to propagate, showed promising
initial results in vitro with peptide nucleic acids (PNAs) [234].
However, although PNAs colocalised to mitochondria in intact cells,
they were not able to cross the IMM. Molecules with greater polarity
have since been designed (cell membrane crossing oligomers,
CMCOs), and CMCO:PNA hybrid molecules have been successfully
targeted and imported into mitochondria in whole cells [235]. Further
research is still necessary to establish their ability to inhibit mtDNA
replication and their effectiveness in vivo. Alternative strategies for
manipulating mtDNA heteroplasmy levels include mitochondria-
targeted restriction endonucleases, capable of distinguishing between
mutated and wild-type genomes. Successful in human cells harbour-
ing pathogenic mutations, in hybrid cells with both rat and mouse
mtDNA and in a mouse model heteroplasmic for the BALB and NZB
mtDNA haplotypes, this approach is limited to mtDNA mutations that
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strate this restriction site need not be unique to the pathogenic
genome [236]. Selective targeting of mutated mtDNA has also been
successfully attempted with a targeted chimaeric zinc ﬁnger DNA
methylase, which can bind and modify, in a sequence-speciﬁc
manner, mutant genomes in cells harbouring the m.8993TNG NARP
mutation [237]. Whilst very promising, the therapeutic use of this
strategy is limited by the need for transfection and successful
expression in defective tissues.
Complementation of mtDNA defects, by allotopic expression of a
gene in a different cellular compartment to its target location, is
another promising approach for treating mitochondrial diseases.
Initial attempts to recover respiratory defects in cybrids harbouring
MT-ATP6 and MT-ND1 mutations, by engineered nuclear expression
of their wild-type proteins [238,239], have been improved recently by
forcing mRNA localisation to the mitochondrial surface, which
ensures maximal mitochondrial translocation of the highly hydro-
phobic polypeptides [240,241]. For mt-tRNA mutations, yeast tRNALys
derivatives can be expressed and imported into mitochondria
within cybrid cells and primary human ﬁbroblasts harbouring
the m.8344ANG MERRF mutation. Imported tRNALys molecules
are correctly aminoacylated, able to participate in mitochondrial
translation, and partially rescue mitochondrial functions [242].
Recently, Rubio et al. [243] have demonstrated the import of cytosolic
tRNAGln(CUG) and tRNAGln(UUG) in rat and humanmitochondria in vivo,
by a mechanism distinct from that of protein import. This discovery
has important implications for the development of future therapies
for mt-tRNA mutations as this process was not thought to normally
occur in human cells. Pathogenic mt-tRNA mutations may also be
rescued through modiﬁcation or overexpression of their cognate
aminoacyl synthetase. Aminoacylation efﬁciency of mutant mt-
tRNAPhe, carrying the m.611GNA MERRF mutation, was signiﬁcantly
improved following modiﬁcation of the mt-tRNA binding domain of
the cognate phenylalanyl-tRNA synthetase [203]. Furthermore, two
recent studies have demonstrated an increase in mutant mt-tRNAVal
[159] and mt-tRNALeu(UUR) [166] steady-state levels following over-
expression of the valyl and leucyl synthetases, respectively. In mutant
m.3243ANG cells, this overexpressionwas capable of recoveringwild-
type RC function. These ﬁndings suggest promising new therapeutic
strategies to treat mt-tRNA diseases.
A variation of allotopic expression is the xenotropic expression of
wild-type genes of other species, encoding proteins with similar
function. Mitochondrial targeting of the S.cerevisiae single subunit
NADH oxidase, Ndi1, has been shown to rescue complex I deﬁciency
in human cells [244] and also protect against neurodegeneration in
rats fed with MPTP, a hallucinogen known to cause a form of
Parkinson's disease (PD) [245]. The use of yeast Ndi1 may thus
represent a promising approach for rescuing any complex I deﬁciency
in patients with PD. Similarly, xenotopic expression of the green alga
Chlamydomonas reinhardtii ATPase 6 (CrATP6) in human cybrid cells
harbouring the m.8993TNG mutation resulted in moderately im-
proved ATP production whilst cellular viability was fully recovered
[246]. These data suggest gene therapeutic approaches for the
treatment of ATP synthase disorders such as NARP and MILS may
be possible. Furthermore, an encouraging strategy for the potential
rescue of mitochondrial COX defects may soon be possible following
the successful transfection and IMM targeting in human cultured cells
of the sea squirt Ciona intestinalis cyanide-insensitive alternative
oxidase (AOX) [247]. Indeed, AOX was well tolerated and transfec-
tants displayed remarkable levels of cyanide resistance to mitochon-
drial metabolite oxidation.
6.3. Prevention of mtDNA disease transmission
The outcome of speciﬁc pregnancies remains unpredictable due
to the genetic bottleneck, which leads to considerable variation inthe proportion of mutant mtDNA in different offspring [248]. This
makes accurate genetic counselling for families affected by mtDNA
mutations extremely challenging. Nonetheless, several approaches
to help minimise the transmission of high mtDNA mutation loads
are being considered. For example, prenatal genetic diagnosis from
chorionic villus sampling or amniocentesis may be performed.
Whilst there is concern whether the mutation load detected in the
prenatal sample would accurately reﬂect the heteroplasmy levels in
other foetal tissues, present evidence suggests that this should not
be a problem [169,249]. Preimplantation genetic diagnosis (PGD) of
mtDNA from the polar body of unfertilised oocytes or from one to
two single cells removed from early embryos prior to implantation
is an alternative approach. This technique may similarly be limited
by tissue-speciﬁc differences in mutational load. However, studies in
heteroplasmic mice have demonstrated almost identical levels of
heteroplasmy between the ooplasm and polar body of the mature
oocyte and also between individual blastomeres [250]. Despite its
promise, PGD has only been successfully completed in one case of
mtDNA disease [251].
Currently, mitochondrial gene replacement offers great potential
for the prevention of human mtDNA disease transmission. Recently,
spindle–chromosome complex transfer from amature primate oocyte
to an enucleated primate egg successfully produced healthy offspring,
in which, importantly, spindle donor mtDNA was not detected [252].
An alternative approach involving pronuclear transfer, the transfer of
the pronuclei from a fertilised zygote of a mother withmtDNA disease
to an enucleated zygote from a healthy donor female, is presently
being investigated in abnormally fertilised human embryos (Turnbull
et al., unpublished data). Previous studies in heteroplasmic mice have
suggested the feasibility of this approach [253]. For comprehensive
reviews regarding the treatment of mitochondrial disease, see
references [235,254,255].
7. Perspectives
Since identiﬁcation of the ﬁrst mtDNA mutations more than
20 years ago, signiﬁcant progress has been made in cataloguing and
understanding the mtDNA defects responsible for the development of
mitochondrial diseases. The continually increasing number of
reported pathogenic mutations within both the mitochondrial and
nuclear genomes and the constantly evolving rules of pathogenicity
make the diagnosis of these disorders ever more challenging. The
implementation of more high-throughput screening approaches
should hopefully improve the situation. Disappointingly, no effective
therapies or cures are presently available for patients with mtDNA
disease. Several exciting and promising experimental approaches for
mtDNA disease treatment are currently being investigated and may
hopefully make their way into the clinic in the near future.
Furthermore, recent research efforts are focusing more and more on
establishing the molecular mechanisms of disease and elucidating the
complex relationships between genotypes and the diverse clinical
phenotypes associated with these disorders. Elucidating the patho-
genesis of mitochondrial disorders will undoubtedly uncover novel
protein targets or molecular pathways that may be exploited for
therapy development. In the meantime, approaches to prevent the
transmission of mitochondrial disease, including PGD, pronuclear
transfer between single cell embryos and spindle-chromosome
transfer between oocytes, are being actively pursued.
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